[서울=뉴스핌] Reporter Wonjin Choi = It is news that Pfizer, a US pharmaceutical company, and Bioentech of Germany have agreed to supply a vaccine to the COVAX Facility, a plan for vaccinating COVAX.
 |
| [로이터=뉴스핌] Reporter Kim Sun-mi = Drops of medicine are falling from the needle against the background of the Pfizer logo, an American pharmaceutical company. 2020.11.27 [email protected] |
According to Reuters on the 21st (local time) citing two sources who are familiar with the matter, Pfizer-Bioentech will officially announce a contract to supply COVAX facility vaccines on the 22nd.
Information on the amount of supply and the price of the vaccine to be paid by Kovacs is not yet known, but sources said the distribution to each country will be relatively small. This is because the vaccine is intended for priority vaccination of healthcare workers in countries served by COVAX.
COVAX is an international project for the joint purchase and distribution of vaccines to developing countries and is jointly operated by the World Health Organization (WHO), the World Vaccine Immunity Association (GAVI), and the Infectious Disease Innovation Association (CEPI).
KOVAX will start supplying the vaccine next month. On the same day, the Ukrainian government announced that the first dose of 210,000 vaccines under the COVAX program is expected to arrive in mid-February, and it will be one of the Modena, Pfizer, and AstraZeneca vaccines.
Kovacs aims to deliver over 2 billion batches to the world this year.